Anti-HER2 dendritic cell vaccine shows promise against DCIS

[News]

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer.

More... (http://www.news-medical.net/news/20120131/Anti-HER2-dendritic-cell-vaccine-shows-promise-against-DCIS.aspx)